Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

David R. Gandara, MD
Published: Monday, Oct 16, 2017



David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC), during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

The most important aspect of FLAURA is that a new-generation inhibitor can be superior to the standard first-generation standard of care in not just efficacy, but toxicity as well, Gandara explains.

Secondly, the data on patients with brain metastases highly favored osimertinib over the first-generation agents, he concludes.

<<< View more from the World Conference on Lung Cancer


David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC), during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

The most important aspect of FLAURA is that a new-generation inhibitor can be superior to the standard first-generation standard of care in not just efficacy, but toxicity as well, Gandara explains.

Secondly, the data on patients with brain metastases highly favored osimertinib over the first-generation agents, he concludes.

<<< View more from the World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x